Pharmacoeconomic evaluation of Suhuang Zhike Capsules using Markov model for inpatients with acute exacerbation of chronic obstructive pulmonary disease.
10.19540/j.cnki.cjcmm.20200910.501
- Author:
Zhi-Heng WANG
1
;
Meng-Pei ZHANG
1
;
Hao-Xiang ZHANG
1
;
Jie PAN
1
;
Kai-Ni ZUO
1
;
Xiao-Mei WANG
1
;
Wen-Tao ZHU
1
Author Information
1. School of Management, Beijing University of Chinese Medicine Beijing 100029, China.
- Publication Type:Journal Article
- Keywords:
AECOPD;
Markov model;
chronic obstructive pulmonary disease(COPD);
cost-utility
- MeSH:
Capsules;
Drugs, Chinese Herbal/therapeutic use*;
Economics, Pharmaceutical;
Humans;
Inpatients;
Pulmonary Disease, Chronic Obstructive/drug therapy*
- From:
China Journal of Chinese Materia Medica
2021;46(10):2588-2593
- CountryChina
- Language:Chinese
-
Abstract:
To evaluate the economics of Suhuang Zhike Capsules in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD) for inpatients. Based on the published clinical research data, cost-utility analysis was used in this study to evaluate the pharmacoeconomics of Suhuang Zhike Capsules in treatment of AECOPD inpatients from the perspective of medical insu-rance. The test group was treated with Suhuang Zhike Capsules combined with conventional Western medicine, and the control group was treated with conventional Western medicine alone. Treeage software was used to construct a pharmacoeconomic model and perform simulation analysis. The results showed that the cost and output of Suhuang Zhike Capsules combined with the conventional Western medicine were 60 010.18 yuan and 1.92 quality adjusted life year(QALYs), respectively in the simulated 3 years of disease treatment. The cost and output of the conventional Western medicine were 96 730.60 yuan and 1.90 QALYs respectively. Suhuang Zhike Capsules combined with conventional Western medicine required lower cost but achieved higher output, showing cost-utility advantages, so this drug combination was a plan with pharmacoeconomic advantages. The sensitivity analysis results showed that the conclusion was relatively stable. Based on the above results, it is believed that as compared with the conventional Western medicine, Suhuang Zhike Capsules combined with conventional Western medicine have lower cost and higher output for the treatment of AECOPD inpatients, and it is a treatment plan with pharmacoeconomic advantages.
